Potential of NOTCH1 Mutation to Predict Anti-PD1 Treatment Outcomes in Patients with Oesophageal Squamous Cell Cancer By Ogkologos - April 23, 2025 823 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from a biomarker analysis from the RATIONALE-302 study Source RELATED ARTICLESMORE FROM AUTHOR FDA Approves Allogeneic Regulatory T Cell-Based Immunotherapy with HSPC and T Cells-vldq for Use in Matched Donor HSCT for Adult Patients with Haematologic Malignancies Combination of mFOLFOX6/Bevacizumab Plus Atezolizumab Prolongs PFS Compared with Atezolizumab in First-Line Treatment of dMMR/MSI-H mCRC Use of YEARS Algorithm, D-dimer Levels, and Performing Risk-Dependent CT Pulmonary Angiography is Safe in Patients with Cancer and Suspected Pulmonary Embolism MOST POPULAR COVID-19 in people with cancer – what we know so far December 4, 2020 2021 ASCO Annual Meeting Research Round Up: Advances in Treating Brain... September 30, 2021 Withdrawal of the Application to Change the EMA Marketing Authorisation for... December 2, 2022 The Childhood Cancer Data Initiative: Transforming the Pediatric Cancer Landscape through... August 15, 2019 Load more HOT NEWS How to Support a Spouse or Partner During Cancer Treatment by... Cómo aprendí a sobrellevar la culpa del superviviente después del cáncer Utility of Genomic Profiling of cfDNA to Inform Clinical Care for... Science Surgery: ‘Can cancers develop in the heart?’
